Clostridioides difficile, a Gram-positive, anaerobic, spore-forming bacillus, has emerged as a predominant pathogen, causing antimicrobial-associated ...
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on ...
For adults with acute sinusitis treated in the outpatient setting, there is no difference in treatment failure with ...
Observational study supports efficacy, safety compared with amoxicillin-clavulanate ...
University of California San Diego researchers have developed a new tool for understanding and modifying any microbiome, ...
A large observational study involving hundreds of thousands of patients in the United States saw no difference in treatment ...
Methodology that is not complete, as well as discrepancies regarding the proposed mode of action of lipoxin A4, are significant weaknesses.
Antibiotics can disrupt the healthy bacteria in your gut. Discover four different ways you can help protect your gut health ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...